*In the European Union and other countries, afatinib is approved under the brand name GIOTRIF®, and in the U.S. under the brand name GILOTRIF™ for use in patients with distinct types of NSCLC. Afatinib is under regulatory review by health authorities in other countries. Afatinib has not yet been approved in other indications. ** Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. Nintedanib is under regulatory review by health authorities in other countries outside the EU. Nintedanib is not approved in other oncology indications. ***Volasertib is an investigational compound and is not yet approved. Its safety and efficacy has not yet been fully established.